{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:57:58Z","timestamp":1778803078320,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":123,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"Acadia Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.prdoa.2025.100342","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T02:55:19Z","timestamp":1746500119000},"page":"100342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Sedation and sleep safety of pimavanserin for Parkinsons\u2019s disease psychosis: Review and exploratory analysis of clinical study data"],"prefix":"10.1016","volume":"12","author":[{"given":"Ana","family":"Berrio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambros","family":"Chrones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-1203","authenticated-orcid":false,"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2025.100342_b0005","series-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects [internet]","article-title":"Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis","author":"Kouli","year":"2018"},{"key":"10.1016\/j.prdoa.2025.100342_b0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","article-title":"Treatment of psychotic symptoms in patients with Parkinson disease","volume":"7","author":"Chen","year":"2017","journal-title":"Ment Health Clin."},{"key":"10.1016\/j.prdoa.2025.100342_b0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson's disease: advances and challenges","volume":"21","author":"Weintraub","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41531-024-00642-0","article-title":"Sleep disorders in Parkinson's disease, an early and multiple problem","volume":"10","author":"Dodet","year":"2024","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.prdoa.2025.100342_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41386-019-0448-y","article-title":"Sleep in Parkinson's disease","volume":"45","author":"Stefani","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.prdoa.2025.100342_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13081202","article-title":"Neurological insights into sleep disorders in Parkinson's disease","volume":"13","author":"Thangaleela","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.prdoa.2025.100342_b0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S1092852900017259","article-title":"Taking a closer look at sleep problems and psychosis in Parkinson's disease","volume":"13","author":"Fernandez","year":"2008","journal-title":"Introduction, CNS Spectr."},{"key":"10.1016\/j.prdoa.2025.100342_b0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1179\/1743132814Y.0000000418","article-title":"Risk factors for visual hallucinations in patients with Parkinson's disease","volume":"37","author":"Gama","year":"2015","journal-title":"Neurol. Res."},{"key":"10.1016\/j.prdoa.2025.100342_b0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/13546805.2013.877385","article-title":"Cognitive correlates of psychosis in patients with Parkinson's disease","volume":"19","author":"Moustafa","year":"2014","journal-title":"Cogn. Neuropsychiatry."},{"key":"10.1016\/j.prdoa.2025.100342_b0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40263-024-01084-1","article-title":"On the optimal diagnosis and the evolving role of pimavanserin in Parkinson's disease psychosis","volume":"38","author":"Pagan","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.prdoa.2025.100342_b0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","article-title":"Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease","volume":"14","author":"Pappert","year":"1999","journal-title":"Mov. Disord."},{"issue":"Pt 4","key":"10.1016\/j.prdoa.2025.100342_b0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.prdoa.2025.100342_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13060914","article-title":"Parkinson's disease: a narrative review on potential molecular mechanisms of sleep disturbances, REM behavior disorder, and melatonin","volume":"13","author":"Samizadeh","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.prdoa.2025.100342_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276736","article-title":"Sleep-related hallucinations in patients with Parkinson's disease","volume":"17","author":"Komagamine","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.prdoa.2025.100342_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.929569","article-title":"Characteristics of sleep structure in Parkinson's disease patients with hallucinations based on polysomnography","volume":"13","author":"Gu","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0080","series-title":"package insert","author":"NUPLAZID (pimavanserin),","year":"2023"},{"key":"10.1016\/j.prdoa.2025.100342_b0085","unstructured":"US Food and Drug Administration, FDA approves first drug to treat hallucinations and delusions associated with Parkinson\u2019s disease, Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-hallucinations-and-delusions-associated-parkinsons-disease, Accessed June 14, 2023."},{"key":"10.1016\/j.prdoa.2025.100342_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-231167","article-title":"Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study","volume":"98","author":"Alva","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.prdoa.2025.100342_b0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","article-title":"Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis","volume":"68","author":"Weintraub","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.639","article-title":"Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study","volume":"7","author":"Yuan","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.prdoa.2025.100342_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","article-title":"Treatment of psychosis and dementia in Parkinson's disease","volume":"16","author":"Goldman","year":"2014","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0110","first-page":"368","article-title":"Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson\u2019s disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P t."},{"key":"10.1016\/j.prdoa.2025.100342_b0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285610389656","article-title":"Quetiapine in the treatment of psychosis in Parkinson's disease","volume":"3","author":"Shotbolt","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.prdoa.2025.100342_b0120","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.prdoa.2025.100342_b0125","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1212\/WNL.57.8.1392","article-title":"Daytime sleepiness and other sleep disorders in Parkinson's disease","volume":"57","author":"Ondo","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2025.100342_b0130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","article-title":"Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences","volume":"12","author":"Pazan","year":"2021","journal-title":"Eur. Geriatr. Med."},{"key":"10.1016\/j.prdoa.2025.100342_b0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic drug-induced somnolence: incidence, mechanisms, and management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.prdoa.2025.100342_b0140","first-page":"3","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller","year":"2004","journal-title":"Prim. Care Companion J. Clin. Psychiatry."},{"key":"10.1016\/j.prdoa.2025.100342_b0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jcpt.12357","article-title":"Quetiapine safety in older adults: a systematic literature review","volume":"41","author":"El-Saifi","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.prdoa.2025.100342_b0150","series-title":"A guide to the management of clozapine-related tolerability and safety concerns","author":"Citrome","year":"2016"},{"key":"10.1016\/j.prdoa.2025.100342_b0155","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.prdoa.2025.100342_b0160","unstructured":"G.W. Arana, An overview of side effects caused by typical antipsychotics, J. Clin. Psychiatry. 61 Suppl 8 (2000) 5-11; discussion 12-13."},{"key":"10.1016\/j.prdoa.2025.100342_b0165","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia","volume":"12","author":"M\u00fchlbauer","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.prdoa.2025.100342_b0170","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.prdoa.2025.100342_b0175","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1080\/09638288.2020.1814878","article-title":"Sleep, caregiver burden, and life satisfaction in Parkinson's disease caregivers: a multinational investigation","volume":"44","author":"Perez","year":"2022","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.prdoa.2025.100342_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.887094","article-title":"Worse sleep quality aggravates the motor and non-motor symptoms in Parkinson's disease","volume":"14","author":"Yi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.prdoa.2025.100342_b0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sleep.2010.10.004","article-title":"Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers","volume":"12","author":"Ancoli-Israel","year":"2011","journal-title":"Sleep Med."},{"key":"10.1016\/j.prdoa.2025.100342_b0190","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/WNF.0000000000000307","article-title":"Nighttime sleep and daytime sleepiness improved with pimavanserin during treatment of Parkinson's disease psychosis","volume":"41","author":"Patel","year":"2018","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.prdoa.2025.100342_b0195","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.prdoa.2025.100342_b0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2021.04.012","article-title":"Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients","volume":"87","author":"S.H. Isaacson, C.G. Ballard, D.L. Kreitzman, B. Coate, J.C. Norton, H.H. Fernandez, T.V. Ilic, J.P. Azulay, J.J. Ferreira, V. Abler, S. Stankovic, G. Study","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2025.100342_b0205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","article-title":"015 Study Group, Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis","volume":"77","author":"Ballard","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2025.100342_b0210","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14740338.2022.2069240","article-title":"Hallucinations and delusions associated with Parkinson\u2019s disease psychosis: safety of current treatments and future directions","volume":"21","author":"Isaacson","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.prdoa.2025.100342_b0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41598-023-49600-5","article-title":"Striatal dopamine neurotransmission is altered in age- and region-specific manner in a Parkinson's disease transgenic mouse","volume":"14","author":"Medina-Luque","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prdoa.2025.100342_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.919778","article-title":"Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis","volume":"13","author":"Abler","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0225","first-page":"16","article-title":"Pimavanserin: a novel drug approved to treat Parkinson's disease psychosis, Innov","volume":"15","author":"Kitten","year":"2018","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.prdoa.2025.100342_b0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.parkreldis.2019.11.009","article-title":"Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies","volume":"69","author":"Horn","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2025.100342_b0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study","volume":"11","author":"Gefvert","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.prdoa.2025.100342_b0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/nedt.2007.3.2.219","article-title":"Quetiapine in the treatment of schizophrenia and related disorders","volume":"3","author":"Riedel","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.prdoa.2025.100342_b0245","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1176\/appi.neuropsych.18080180","article-title":"Systematic literature review of quetiapine for the treatment of psychosis in patients with Parkinsonism","volume":"31","author":"Chen","year":"2019","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.prdoa.2025.100342_b0250","first-page":"703","article-title":"Treatment of drug-induced psychosis in Parkinson's disease with clozapine","volume":"60","author":"Greene","year":"1993","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0255","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prdoa.2025.100342_b0260","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.prdoa.2025.100342_b0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.prdoa.2025.100342_b0270","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson's disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract."},{"key":"10.1016\/j.prdoa.2025.100342_b0275","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/JCP.0000000000001735","article-title":"Clinician Reasons for Stopping Clozapine: A Retrospective Cohort Study","volume":"43","author":"Grover","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.prdoa.2025.100342_b0280","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","article-title":"Reasons for discontinuing clozapine: A cohort study of patients commencing treatment","volume":"174","author":"Legge","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.prdoa.2025.100342_b0285","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12883-021-02265-x","article-title":"Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?","volume":"21","author":"Pham Nguyen","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.prdoa.2025.100342_b0290","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0019-5545.196978","article-title":"Clinical Practice Guidelines for Sleep Disorders, The","volume":"59","author":"Gupta","year":"2017","journal-title":"Indian J. Psychiatry."},{"key":"10.1016\/j.prdoa.2025.100342_b0295","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","article-title":"Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey","volume":"70","author":"Barnes","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.prdoa.2025.100342_b0300","series-title":"Philadelphia","author":"A. Mane, B. Kathiriya, Y. Patidar, V. Patel, A. Singhal, B. Patel, S. Choudhury, R. Varadarajulu, A. Pattojoshi, B. Solanki, A. Sharma, A. Pande, K. Parmar, S. Jayalekshmi, R. Mridula, N. Sundarachary, P. Walzade, S. Ramteke, D. Kumar, P. Kumar, D. Sonawane, P. Devkare, M. Rajurkar, D. Patil, P. Ghadge, S. Mehta, A phase 3, randomized, assessor-blind, active-controlled study of pimavanserin in comparison with quetiapine in Parkinson\u2019s disease psychosis, Presented at: International Congress of Parkinson\u2019s Disease and Movement Disorders, September 27 - October 1","year":"2024"},{"key":"10.1016\/j.prdoa.2025.100342_b0305","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/gps.5384","article-title":"The minimum clinically important difference on the sleep disorders inventory for people with dementia","volume":"35","author":"Webster","year":"2020","journal-title":"Int. J. Geriatr. Psychiatry."}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:19:22Z","timestamp":1775819962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112525000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":61,"alternative-id":["S2590112525000465"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100342","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sedation and sleep safety of pimavanserin for Parkinsons\u2019s disease psychosis: Review and exploratory analysis of clinical study data","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100342"}}